Contact
searchSearch
HMP Global

Nasal Polyps Topic Center

Featured Article

News
Eosinophilic Esophagitis Symptoms Improved by Monoclonal Antibody Therapy
02/25/2022
Jolynn Tumolo
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment...
02/25/2022
First Report Managed Care
News
Dupilumab Improves Symptoms in Patients With Severe CRSwNP and Comorbid Asthma
10/27/2021
Jolynn Tumolo
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat...
10/27/2021
First Report Managed Care
Headshot of Peter Lio, MD, FAAD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Addressing Unmet Needs in Patients With Type 2 Inflammatory Conditions
09/28/2021
Edan Stanley
Peter Lio, MD, FAAD, clinical assistant professor of dermatology & pediatrics, Northwestern University Feinberg School of Medicine, and founding director, Chicago Integrative Eczema Center, discusses the common challenges associated with...
Peter Lio, MD, FAAD, clinical assistant professor of dermatology & pediatrics, Northwestern University Feinberg School of Medicine, and founding director, Chicago Integrative Eczema Center, discusses the common challenges associated with...
Peter Lio, MD, FAAD, clinical...
09/28/2021
First Report Managed Care
News
Dupilumab offers relief for severe chronic rhinosinusitis with nasal polyps
09/27/2019
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and...
09/27/2019
First Report Managed Care
News
Lower QoL Among Patients With Chronic Rhinosinusitis With Nasal Polyps
07/29/2019
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that...
07/29/2019
First Report Managed Care
News
First Treatment Approved for Chronic Rhinosinusitis With Nasal Polyps
06/26/2019
Dupixent (dupilumab; Regeneron Pharmaceuticals and Sanofi), is the first treatment approved by the FDA for the treatment of inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupixent (dupilumab; Regeneron Pharmaceuticals and Sanofi), is the first treatment approved by the FDA for the treatment of inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupixent (dupilumab; Regeneron...
06/26/2019
First Report Managed Care
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): The Challenge of Long-term Control

Newsfeed

News
Eosinophilic Esophagitis Symptoms Improved by Monoclonal Antibody Therapy
02/25/2022
Jolynn Tumolo
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment...
02/25/2022
First Report Managed Care
News
Dupilumab Improves Symptoms in Patients With Severe CRSwNP and Comorbid Asthma
10/27/2021
Jolynn Tumolo
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat...
10/27/2021
First Report Managed Care
News
Dupilumab offers relief for severe chronic rhinosinusitis with nasal polyps
09/27/2019
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and...
09/27/2019
First Report Managed Care
News
Lower QoL Among Patients With Chronic Rhinosinusitis With Nasal Polyps
07/29/2019
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that...
07/29/2019
First Report Managed Care
News
First Treatment Approved for Chronic Rhinosinusitis With Nasal Polyps
06/26/2019
Dupixent (dupilumab; Regeneron Pharmaceuticals and Sanofi), is the first treatment approved by the FDA for the treatment of inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupixent (dupilumab; Regeneron Pharmaceuticals and Sanofi), is the first treatment approved by the FDA for the treatment of inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupixent (dupilumab; Regeneron...
06/26/2019
First Report Managed Care
News
FDA Issues Final Guidance on Biosimilar Prior Approval Supplements
09/10/2025
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) has finalized guidance clarifying 6 categories of biosimilar prior approval supplements, setting review goals that could shape timelines for new indications and payer coverage decisions.
The US Food and Drug Administration (FDA) has finalized guidance clarifying 6 categories of biosimilar prior approval supplements, setting review goals that could shape timelines for new indications and payer coverage decisions.
The US Food and Drug...
09/10/2025
First Report Managed Care
News
High Health Care Burden Among People with Hemophilia A Experiencing Bleeding or Joint Complications
09/10/2025
Juliet Gallagher
New real-world evidence shows that people with hemophilia A who experience bleeding or joint complications face significantly higher health care utilization and comorbidity burden.
New real-world evidence shows that people with hemophilia A who experience bleeding or joint complications face significantly higher health care utilization and comorbidity burden.
New real-world evidence shows...
09/10/2025
First Report Managed Care
News
Confronting the HIV Epidemic: Addressing Gaps in Access, Adherence, and Equity
09/02/2025
Juliet Gallagher
At a recent AMCP conference, health care leaders Maria Lopes, MD, and Steve Cohen, MD, highlighted the persistent and unique challenges of HIV management in the US, emphasizing that despite medical advancements, HIV remains classified as an...
At a recent AMCP conference, health care leaders Maria Lopes, MD, and Steve Cohen, MD, highlighted the persistent and unique challenges of HIV management in the US, emphasizing that despite medical advancements, HIV remains classified as an...
At a recent AMCP conference,...
09/02/2025
First Report Managed Care
News
Industry Payments and Their Role in MS Drug Selection Among High-Volume Prescribers
08/28/2025
Juliet Gallagher
A recent observational study explored the prevalence of industry payments to neurologists who prescribe multiple sclerosis (MS) disease-modifying therapies (DMTs), uncovering significant associations between such payments and prescribing...
A recent observational study explored the prevalence of industry payments to neurologists who prescribe multiple sclerosis (MS) disease-modifying therapies (DMTs), uncovering significant associations between such payments and prescribing...
A recent observational study...
08/28/2025
First Report Managed Care
News
Medicare Advantage Plans See Double-Digit Satisfaction Drop as Medical Costs Soar
08/22/2025
Juliet Gallagher
Member satisfaction with Medicare Advantage (MA) plans has seen a significant decline, according to J.D. Power’s 2025 report, reflecting a broader set of financial and policy pressures now facing the MA landscape.
Member satisfaction with Medicare Advantage (MA) plans has seen a significant decline, according to J.D. Power’s 2025 report, reflecting a broader set of financial and policy pressures now facing the MA landscape.
Member satisfaction with...
08/22/2025
First Report Managed Care
News
Expanding Assertive Community Treatment to Transform Care for Complex Patients
08/20/2025
Lisa Kuhns, PhD, MD
A new study shows that health systems can rely on assertive community treatment (ACT), which has strong evidence supporting its effectiveness for treating the most complex, least engaged patients.
A new study shows that health systems can rely on assertive community treatment (ACT), which has strong evidence supporting its effectiveness for treating the most complex, least engaged patients.
A new study shows that health...
08/20/2025
First Report Managed Care
News
AAM White Paper Spotlights Legislative Path to Breaking Biosimilar Patent Barriers
08/18/2025
Grace Taylor, MS, MA
A recent white paper from the Association for Accessible Medicines exposes how brand-name drug patent tactics block biosimilar access and urges Congress to act on 3 key reforms to lower drug costs.
A recent white paper from the Association for Accessible Medicines exposes how brand-name drug patent tactics block biosimilar access and urges Congress to act on 3 key reforms to lower drug costs.
A recent white paper from the...
08/18/2025
First Report Managed Care
News
FDA Expands Approval of Alhemo for Hemophilia A and B Without Inhibitors
08/14/2025
Juliet Gallagher
Novo Nordisk has announced the US Food and Drug Administration (FDA) approval of Alhemo (concizumab-mtci) for use as a once-daily subcutaneous prophylactic treatment in people 12 years and older with hemophilia A or B (HA/HB) without...
Novo Nordisk has announced the US Food and Drug Administration (FDA) approval of Alhemo (concizumab-mtci) for use as a once-daily subcutaneous prophylactic treatment in people 12 years and older with hemophilia A or B (HA/HB) without...
Novo Nordisk has announced the...
08/14/2025
First Report Managed Care
News
High-Efficacy Multiple Sclerosis Therapies Linked to Fewer Emergency Department Visits and Lower Risk
08/13/2025
Lisa Kuhns, PhD, MD
High-efficacy disease-modifying therapies (DMTs) for multiple sclerosis (MS) are linked to a reduced likelihood of emergency department (ED) visits, according to a study published in Neurology.
High-efficacy disease-modifying therapies (DMTs) for multiple sclerosis (MS) are linked to a reduced likelihood of emergency department (ED) visits, according to a study published in Neurology.
High-efficacy disease-modifying...
08/13/2025
First Report Managed Care
News
Roctavian Demonstrates Sustained Efficacy and Safety in Patients With Hemophilia A
08/04/2025
Grace Taylor, MS, MA
Five-year data from BioMarin’s phase 3 trial reveals Roctavian’s long-term efficacy, safety, and quality-of-life benefits for adults with severe hemophilia A.
Five-year data from BioMarin’s phase 3 trial reveals Roctavian’s long-term efficacy, safety, and quality-of-life benefits for adults with severe hemophilia A.
Five-year data from BioMarin’s...
08/04/2025
First Report Managed Care

Recent Articles

News
Eosinophilic Esophagitis Symptoms Improved by Monoclonal Antibody Therapy
02/25/2022
Jolynn Tumolo
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment...
02/25/2022
First Report Managed Care
News
Dupilumab Improves Symptoms in Patients With Severe CRSwNP and Comorbid Asthma
10/27/2021
Jolynn Tumolo
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat...
10/27/2021
First Report Managed Care
Headshot of Peter Lio, MD, FAAD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Addressing Unmet Needs in Patients With Type 2 Inflammatory Conditions
09/28/2021
Edan Stanley
Peter Lio, MD, FAAD, clinical assistant professor of dermatology & pediatrics, Northwestern University Feinberg School of Medicine, and founding director, Chicago Integrative Eczema Center, discusses the common challenges associated with...
Peter Lio, MD, FAAD, clinical assistant professor of dermatology & pediatrics, Northwestern University Feinberg School of Medicine, and founding director, Chicago Integrative Eczema Center, discusses the common challenges associated with...
Peter Lio, MD, FAAD, clinical...
09/28/2021
First Report Managed Care
News
Dupilumab offers relief for severe chronic rhinosinusitis with nasal polyps
09/27/2019
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and...
09/27/2019
First Report Managed Care
News
Lower QoL Among Patients With Chronic Rhinosinusitis With Nasal Polyps
07/29/2019
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that...
07/29/2019
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use